ANI-7 NEW
| Price | $34 | $59 | $113 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: ANI-7 | CAS No.: 931417-26-4 |
| Purity: 99.21% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | ANI-7 |
| Description | ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM). |
| In vitro | ANI-7 (2.5 μM; 24 hours; MCF10A and MDA-MB-468 cells) treatment induces significant S-phase and G2 + M-phase cell cycle arrest within 24 hours in MDA-MB-468 cells. ANI-7 (2 μM; 12-24 hours; MDA-MB-468 cells) significantly increases CHK2 content and phosphorylation and induces a significant increase in H2AX?, indicating DNA double-strand damage. GI50 values show ANI-7 has a GI50 of 0.38 μM in MCF-7 cells, while values of 3.0-42 μM are seen in lung, colon, ovary, neuronal, glial, prostate, and pancreas cell lines. The A431 vulva cell line shows appreciable growth inhibition (GI50 of 0.51 μM) by ANI-7. ANI-7 potently inhibits T47D, ZR-75-1, MCF-7, SKBR3, and MDA-MB-468 breast cancer cells (GI50 range 0.16-0.38 μM), moderately inhibits BT20 and BT474 cells (GI50 range 1-2 μM), and essentially fails to inhibit MDA-MB-231 and MCF10A cells (GI50 range 17-26 μM). Additionally, ANI-7 maintains its inhibitory effect on drug-resistant cells (MCF-7/VP16: GI50 of 0.21 μM) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (171.02 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.6 mM), Sonication is recommended. |
| Keywords | Chk2 | ANI-7 | ANI7 | ANI 7 |
| Inhibitors Related | Rabusertib | Diosmin | Prexasertib | PD0166285 | Sudan IV | 2-Mercaptobenzothiazole | Benzyl butyl phthalate | 1-Hydroxypyrene | Skatole | L-Kynurenine | Indole-3-carbinol | Dibenzothiophene |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Post-Translational Modification Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:444020-71-7
-
CAS:61210-21-7
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhuyan (Hainan) Biotechnology Co., LTD
|
2026-05-22 | |||
|
VIP2Y
|
Shanghai Yongzeng Technology Co.,Ltd
|
2026-06-02 | ||
| $34.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $34.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-13 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY